A new study sheds light on proteins in particles called extracellular vesicles, which are released by tumor cells into the bloodstream and promote the spread of cancer. The findings suggest how a blood test involving these vesicles might be used to diagnose cancer in the future, avoiding the need for invasive surgical biopsies.
The oncogenic herpesvirus (HHV8 or KSHV) causes a cancer known as Kaposi’s Sarcoma. An international team of scientists led by the University of Helsinki has discovered key factors that control the genome maintenance and replication of a virus responsible for lymphatic vascular cancer. Kaposi Sarcoma (KS) is the most common cancer among Aids patients and it is often seen in sub Saharan and…
Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated, often before there are any clinical signs or symptoms of the disease. In a paper published in the leading cancer journal Annals of Oncology, the researchers show that the test, which could eventually be used in national cancer screening…
Biologists have discovered a way to stop cells from one of the most aggressive types of breast cancer spreading in the lab. The study points towards new avenues of research to combat the devastating disease. The results of the study of Triple-Negative Breast Cancer by the team from the Universities of Manchester, Glasgow and Sheffield and funded by Breast Cancer Now are published in Oncogene.…
An enthralling insight into the care that could be offered to cancer patients of the future was presented by cancer imaging expert Professor Regina Beets-Tan during her a keynote presentation at the recent British Institute of Radiology congress. In the session ‘Oncologic imaging: Future perspectives’, the professor outlined what a Multi-Disciplinary Team (MDT) of the future – a team in…
MRI is now indispensable for diagnosing diseases and monitoring therapies. However, the ongoing discussion on gadolinium deposits in the brain has intensified the search for alternatives. Dr Daniel Paech of the German Cancer Research Centre in Heidelberg, Germany, discussed potential solutions to acquire high-quality images without contrast agents.
Scientists from the Case Western Reserve University digital imaging lab use Artificial Intelligence (AI) to predict which lung-cancer patients will benefit from expensive immunotherapy. This is done by teaching a computer to find previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy…
Doctors who give advanced breast cancer patients just one estimate, such as 12 months, for the average amount of time they are expected to live are only accurate 20-30% of the time, according to Dr Belinda Kiely, medical oncologist and senior research fellow at the University of Sydney, Australia.
For lung cancer patients, life expectancy has hardly improved since 1970. A ten-year survival is 5%, making this the leading cause of death among all cancers. One reason is that, in most cases, the disease is diagnosed far too late. Professor Mathias Prokop is among leading advocates of low-dose CT screening for lung cancer for high risk patients.
Researchers at Leipzig University and Leipzig University Hospital (UKL) have discovered that tumour growth and tissue invasion by cancer cells can be predicted based on the ontogenetic distance between tissues.
Cancer treatment could be dramatically improved by an invention at the University of Waterloo to precisely locate the edges of tumors during surgery to remove them.
The Geneva University Hospitals (HUG) is the first European university hospital to utilize IBM’s artificial intelligence (AI) technology to help uncover therapeutic options for cancer patients. HUG will use the IBM Watson Health’s precision oncology offering, Watson for Genomics, an AI tool that enables oncologists to provide patients with more personalized, evidence-based cancer care. Using…
In terms of success in revolutionary cancer treatment, molecular genetic examination procedures have developed immensely over recent years. They now range from conventional polymerase chain reactions (PCR) or fluorescence-in-situ hybridisation (FISH) to Next Generation Sequencing (NGS) with analysis of the entire exome or genome (Whole-Exome, WES or Whole-Genome, WGS) and of the transcriptome…
Professor Regina Beets-Tan has been appointed to the mission board of the EU research mission on cancer, part of the European Commission’s research initiative known as Horizon Europe. She has been selected to serve on the 15-member board for the cancer mission, tasked with shaping their mission and further defining what research receives funding within the cancer mission’s mandate, beginning…
Researchers identified how to kill therapy-resistant cells in hypoxic tumors and in cells arising in the von Hippel-Lindau hereditary cancer. In a recent publication in PNAS, the research group identified how to kill therapy-resistant cells in hypoxic tumors and in cells arising in the von Hippel-Lindau (VHL) hereditary cancer.
Prostate-specific membrane antigen imaging should be the positron emission tomography imaging agent of choice for men who have a prostate cancer recurrence after radical prostatectomy, which needs to be detected and located. For these men, it should become the standard of care, new research shows.
Nurses’ knowledge of cancer and screening processes varies significantly across the globe – potentially resulting in unnecessary deaths where knowledge falls short – new research reports. In the first study of its kind, which was now published in the European Journal of Oncology Nursing, researchers from the University of Surrey investigated nurses’ awareness of cancer warning signs,…
Cancers with the same genetic weaknesses respond differently to targeted drugs depending on the tumour type of the patient, new research reveals. The study is set to prompt changes in thinking around precision medicine—because it shows that the genetics of a patient's cancer may not always be enough to tell whether it will respond to a treatment. The researchers are already starting to design…
Immuno-oncology is a therapy in which the body’s immune system treats a tumour. Dr Eric Borges, from the Research and Development Centre at Boehringer Ingelheim Pharma GmbH in Germany, explains why this is revolutionary. Unlike conventional cancer therapies, with immuno-oncology the tumour cell is not the direct target, it’s the patient’s immune system. The medication stimulates this to…
An anti-inflammatory drug called ketorolac, given before surgery, can promote long-term survival in animal models of cancer metastasis, a team of scientists has found. Furthermore, so-called "pro-resolution" therapies can also trigger the immune system to eliminate metastatic cells. The research also suggests that flanking chemotherapy with anti-inflammatory drugs can unleash anti-tumor…
Wilmot Cancer Institute scientists believe they have figured out why a commonly used drug to treat late-stage prostate cancer often stops working after four or five months and appears to have a dual function that later turns the cancer into a relentless aggressor.
An international group of researchers has found that antibodies to the human papilloma virus type 16 (HPV16) develop in the body between six to 40 years prior to a clinical diagnosis of throat cancer, and their presence indicates a strong increased risk of the disease.
Doctors could soon get some help from an artificial intelligence tool when diagnosing brain aneurysms—bulges in blood vessels in the brain that can leak or burst open, potentially leading to stroke, brain damage or death.
IBA (Ion Beam Applications S.A.) announces the launch of myQA iON at the 2019 PTCOG conference. myQA iON significantly reduces the time needed for patient QA: The use of PT machine log files, process automation, task-based workflows, and the latest web technologies significantly increase QA efficiency while ensuring patient treatment safety. Compared to conventional detector measurements (at…
We all know someone affected by the battle against cancer. And we know that treatments can be quite efficient at shrinking the tumor but too often, they can’t kill all the cells, and so it may come back. With some aggressive types of cancer, the problem is so great that there is very little that can be done for the patients.